BACKGROUND: Many patients seeking bariatric surgery have a history of mood disorders and are actively prescribed antidepressants. While extensive documentation exists on the impact of weight loss surgery on reductions in cardiac, diabetic, and hypertensive medications, little is known about the impact of bariatric surgery on the use of antidepressant medications. METHODS: A retrospective study of 439 patients who had undergone Roux-en-Y gastric bypass (RYGB) from January 2001 to November 2004 was examined for postoperative changes in the use of antidepressant medications. RESULTS: After RYGB, 23% of the patients had an increase in their antidepressant use, 40% continued to require the same antidepressant, 18% had a change in antidepressant medication, and only 16% had a decrease or discontinued their antidepressant. CONCLUSION: Unlike most medications, antidepressant usage did not decrease in the majority of patients after RYGB. These results highlight the prevalence of antidepressant prescription use in patients before and after RYGB and support the need for the careful monitoring of depressive symptoms.
BACKGROUND: Many patients seeking bariatric surgery have a history of mood disorders and are actively prescribed antidepressants. While extensive documentation exists on the impact of weight loss surgery on reductions in cardiac, diabetic, and hypertensive medications, little is known about the impact of bariatric surgery on the use of antidepressant medications. METHODS: A retrospective study of 439 patients who had undergone Roux-en-Y gastric bypass (RYGB) from January 2001 to November 2004 was examined for postoperative changes in the use of antidepressant medications. RESULTS: After RYGB, 23% of the patients had an increase in their antidepressant use, 40% continued to require the same antidepressant, 18% had a change in antidepressant medication, and only 16% had a decrease or discontinued their antidepressant. CONCLUSION: Unlike most medications, antidepressant usage did not decrease in the majority of patients after RYGB. These results highlight the prevalence of antidepressant prescription use in patients before and after RYGB and support the need for the careful monitoring of depressive symptoms.
Authors: John A Batsis; Abel Romero-Corral; Maria L Collazo-Clavell; Michael G Sarr; Virend K Somers; Francisco Lopez-Jimenez Journal: Mayo Clin Proc Date: 2008-08 Impact factor: 7.616
Authors: Chad E Potteiger; Prakash R Paragi; Nicholas A Inverso; Christopher Still; Mary Jane Reed; William Strodel; Marc Rogers; Anthony Petrick Journal: Obes Surg Date: 2004 Jun-Jul Impact factor: 4.129
Authors: Marney A White; Melissa A Kalarchian; Michele D Levine; Robin M Masheb; Marsha D Marcus; Carlos M Grilo Journal: Obes Surg Date: 2015-10 Impact factor: 4.129
Authors: Jan Peter Yska; Susanne van der Linde; Véronique V Tapper; Jan A Apers; Marloes Emous; Erik R Totté; Bob Wilffert; Eric N van Roon Journal: Obes Surg Date: 2013-06 Impact factor: 4.129
Authors: Maurizio De Luca; Luigi Angrisani; Jacques Himpens; Luca Busetto; Nicola Scopinaro; Rudolf Weiner; Alberto Sartori; Christine Stier; Muffazal Lakdawala; Aparna G Bhasker; Henry Buchwald; John Dixon; Sonja Chiappetta; Hans-Christian Kolberg; Gema Frühbeck; David B Sarwer; Michel Suter; Emanuele Soricelli; Mattias Blüher; Ramon Vilallonga; Arya Sharma; Scott Shikora Journal: Obes Surg Date: 2016-08 Impact factor: 4.129
Authors: Afton M Koball; Susan M Himes; Leslie Sim; Matthew M Clark; Maria L Collazo-Clavell; Manpreet Mundi; Todd Kellogg; Karen Graszer; Karen B Grothe Journal: Obes Surg Date: 2016-07 Impact factor: 4.129
Authors: Jin Hee Shin; Mathias Worni; Anthony W Castleberry; Ricardo Pietrobon; Philip A Omotosho; Mina Silberberg; Truls Østbye Journal: Obes Surg Date: 2013-05 Impact factor: 4.129
Authors: Amy L Kennedy; Tracy Nelson; Stefan Pettine; Benjamin F Miller; Karyn L Hamilton; Elise L Donovan Journal: Obes Surg Date: 2014-05 Impact factor: 4.129